Shopping Cart
- Remove All
Your shopping cart is currently empty
Quisinostat
🥰Excellent
Catalog No. T6055Cas No. 875320-29-9
Alias JNJ-26481585
Quisinostat (JNJ-26481585) (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7.
Quisinostat
🥰Excellent
Purity: 96.01%
Catalog No. T6055Alias JNJ-26481585Cas No. 875320-29-9
Quisinostat (JNJ-26481585) (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $54 | In Stock | |
| 2 mg | $78 | In Stock | |
| 5 mg | $126 | In Stock | |
| 10 mg | $225 | In Stock | |
| 25 mg | $349 | In Stock | |
| 50 mg | $450 | In Stock | |
| 100 mg | $638 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $142 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Quisinostat"
Tributyrin
NSC-661583, NSC661583, NSC 661583
T1967660-01-5
Tributyrin (Glyceryl tributyrate), a neutral short-chain fatty acid triglyceride, is a stable and rapidly absorbed prodrug of Butyric Acid. It diffuses through biological membranes and is metabolized by intracellular lipases, releasing effective butyrate directly into cells in vivo, exhibiting potent proapoptotic, antiproliferative, and differentiation-inducing effects.
- $50
Size
QTY
Dextran sulfate sodium salt (MW 4500-5500)
Cited
DSS, Dextran sulfate sodium salt (MW 4500-5500)
T136479011-18-1
Dextran sulfate sodium salt (MW 4500-5500) is an anhydrous glucose polymer with a molecular weight range of 4500-5500. It inhibits human immunodeficiency virus replication by preventing viral adsorption to host cells and is commonly used to model inflammatory bowel disease. The high negative charge from its sulfate groups damages the intestinal mucosal barrier, leading to intestinal barrier dysfunction, macrophage impairment, and bacterial flora disorder.
- $39
Size
QTY
CitedHydroxychloroquine Cited
2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol
T9287118-42-3
Hydroxychloroquine (2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol) (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19.
- $30
Size
QTY
CitedPaeonol
Peonol
T2900552-41-0
Paeonol (Peonol) is an active extraction from Paeonia suffruticosa. Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively.
- $46
Size
QTY
Guanidine hydrochloride
Guanidinium chloride, Guanidine HCl, Aminoformamidine Hydrochloride, Aminoformamidine HCl
T041550-01-1
Guanidine hydrochloride (Aminoformamidine Hydrochloride) is a strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant.
- $29
Size
QTY
Naringin Cited
Naringoside
T059510236-47-2
Naringin (Naringoside), a flavanone glycoside, exerts various of pharmacological effects such as blood lipid lowering, antioxidant activity, anticancer activity, and inhibition of cytochrome P450 enzymes.
- $35
Size
QTY
CitedStavudine
Sanilvudine, NSC 163661, d4T, BMY-27857
T14043056-17-5
Stavudine (BMY-27857), a nucleoside reverse transcriptase inhibitor analog of thymidine, has activity against HIV.
ApoptosisAutophagyHIV ProteaseNOD-like Receptor (NLR)Nucleoside Antimetabolite/AnalogReverse Transcriptase
- $33
Size
QTY
Sodium 4-phenylbutyrate Cited
TriButyrate, Sodium Phenylbutyrate, Buphenyl
T15351716-12-7
Sodium 4-phenylbutyrate (TriButyrate), a transcriptional regulator, reversibly inhibits class I and II histone deacetylases (HDACs )resulting in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.
- $38
Size
QTY
CitedL-Glutamic acid
glutamic acid, glutacid, (S)-Glutamic acid, (+)-L-Glutamic acid
T2A249756-86-0
L-Glutamic acid (Glutaminol) acts as an excitatory transmitter, shows a direct activating effect on the release of DA from dopaminergic terminals.
- $42
Size
QTY
Valproic Acid
Cited
VPA, Sodium valproate, Depakine, 2-Propylvaleric Acid, 2-Propylpentanoic Acid
T706499-66-1
Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that inhibits HDAC1 activity, induces HDAC2 degradation, and is orally active. Valproic Acid can be used in epilepsy and bipolar disorder research.
- $50
Size
QTY
CitedL-Ascorbic acid Cited
Vitamin C, L-Ascorbate, L(+)-Ascorbic acid, Ascorbic acid
T092850-81-7
L-Ascorbic acid (Vitamin C) is a natural product that is a potent reducing agent and antioxidant. L-Ascorbic acid functions in fighting bacterial infections, in detoxifying reactions, and in the formation of collagen. L-Ascorbic acid is used in the treatment of scurvy.
- $42
Size
QTY
Cited
ZD1839
T1181184475-35-2
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
- $40
- $50
Size
QTY
CitedSelect Batch
Purity:96.01%
Contact us for more batch information
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.Product Introduction
Bioactivity
Chemical Properties
| Description | Quisinostat (JNJ-26481585) (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. |
| Targets&IC50 | HDAC1:0.11 nM |
| In vitro | Quisinostat exerts broad-spectrum antiproliferative activity against a wide panel of cancer cell lines including lung, colon, breast, prostate, and ovarian cell lines at nanomolar concentrations. JNJ-26481585 shows activity toward all HDAC enzymes tested with highest potency in vitro observed toward recombinant HDAC1 (IC50, 0.11±0.03 nM), which is comparable with the potency observed toward HDAC1-immunoprecipitated complexes from tumor cells (IC50, 0.16±0.02 nM). Lowest in vitro potency is observed toward HDAC6, 7 and 9 (IC50, 32.1-119 nM) [1]. |
| In vivo | Quisinostat induces continuous H3 acetylation in tumor tissue in vivo. Quisinostat, a "second-generation" HDAC inhibitor with prolonged pharmacodynamic response in vivo. In agreement with the hypothesis, Quisinostat showed superior efficacy compared with both standard of care agents and first-generation HDAC inhibitors in preClinicalal tumor models. These studies suggest that an HDAC inhibitor with continuous pharmacodynamic activity may show activity in solid tumor malignancies[1]. |
| Alias | JNJ-26481585 |
| Molecular Weight | 394.47 |
| Formula | C21H26N6O2 |
| Cas No. | 875320-29-9 |
| Smiles | Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12 |
| Relative Density. | 1.358g/cm3 |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 79 mg/mL (200.26 mM) Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Quisinostat | purchase Quisinostat | Quisinostat cost | order Quisinostat | Quisinostat chemical structure | Quisinostat in vivo | Quisinostat in vitro | Quisinostat formula | Quisinostat molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.